A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

by Berman, R.M, Chan, N., Chen, S., Coric, V., Girda, E., Groisberg, R., Malhotra, J., Mehnert, J.M, Palmeri, M., Saraiya, B., Saunders, T., Shih, W., Silk, A.W, Spencer, K., Vieth, J., Zloza, A.
Published 2022

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

by Chan, N., Chan, T., de Meritens, A.B, Ganesan, S., Girda, E., Groisberg, R., Jabbour, S.K, Leiser, A., Malhotra, J., Mayer, T., Mehnert, J., Palmeri, M., Popli, P., Riedlinger, G., Silk, A.W, Spencer, K., Stephenson, R., Subbiah, V.
Published 2022